ZAPetite News & Updates

  • To translate our bench work to market, we have conducted market analysis through the NSERC Lab2Market grant and participated in the University of Toronto early-stage technologies program (UTEST; 2022). Due to the novelty of our discovery, we have patented the use of ZAP-100™ as an appetite suppressant with a PCT patent filed in July 2023.

  • At PANS2024 in Brazil, we were thrilled to present and share our work on the appetite suppressant and weight loss effects of ZAP-100™ with researchers in North and South America.

  • At ENDO2024 in Boston, USA, we presented our newest finding of ZAP-100™ to improve glucose tolerance and neuronal insulin sensitivity in the hypothalamus.

  • We are proud to welcome Dr. Steven Splinter as ZAPetite’s fractional CEO. Dr. Splinter brings over 25 years of executive leadership in biotechnology, commercialization, and intellectual property strategy. He previously served as Chief Technology Officer at Radient Technologies, where he led the development and scaling of novel natural product extraction platforms. He is currently a Project Coordinator and IP Specialist at the Conestoga Centre for Commercialization and an Entrepreneur-in-Residence with the Lab2Market program, advising Canada’s top emerging STEM ventures. With a PhD in Engineering Science from Western University and a proven track record in translating IP into market-ready technologies, Dr. Splinter brings invaluable experience to guide ZAPetite’s transition from preclinical development to clinical and commercial success.

  • ZAPetite has been selected to join the 2025 Lab2Market Launch cohort. Through this national innovation program, we will refine our business model, validate customer demand, and build strategic connections to accelerate commercialization of ZAP-100™.

  • We are currently completing our final preclinical toxicology and formulation studies in preparation for first-in-human trials, targeted for January 2026. This milestone will mark a pivotal shift from bench discovery to clinical development.

  • As part of our go-to-market strategy, we are actively engaging with supplement industry leaders to evaluate future partnership opportunities for scale-up and distribution. Our focus is on aligning with groups that share our commitment to safe, effective, and science-backed appetite support.